ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis Sheds RNAi Portfolio

by Lisa M. Jarvis
March 16, 2015 | APPEARED IN VOLUME 93, ISSUE 11

RNAi-based drug developer Arrowhead Research will pay Novartis $10 million in cash and $25 million in stock to acquire its RNAi portfolio. The deal includes intellectual property related to RNAi therapeutics and three preclinical drug candidates. Novartis built its RNAi portfolio, which includes the intellectual property related to 30 drug targets, through a five-year pact with another RNAi drug developer, Alnylam. During the course of that collaboration, which ended in 2010, Novartis paid Alnylam $125 million in R&D funding.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment